These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31823667)

  • 21. Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin.
    Lück HJ; Thomssen C; Du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):36-9. PubMed ID: 9516602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.
    Lee YR; Kang MH; Park HM
    Can Vet J; 2015 Jun; 56(6):571-4. PubMed ID: 26028676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioinformatic analysis of peripheral blood miRNA of breast cancer patients in relation with anthracycline cardiotoxicity.
    Yadi W; Shurui C; Tong Z; Suxian C; Qing T; Dongning H
    BMC Cardiovasc Disord; 2020 Feb; 20(1):43. PubMed ID: 32013934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice.
    Santucci L; Mencarelli A; Renga B; Ceccobelli D; Pasut G; Veronese FM; Distrutti E; Fiorucci S
    Anticancer Drugs; 2007 Oct; 18(9):1081-91. PubMed ID: 17704659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
    Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
    Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early assessment of the left ventricular function by epirubicin-induced cardiotoxicity in postoperative breast cancer patients.
    Luo R; Cui H; Huang D; Li G
    Echocardiography; 2017 Nov; 34(11):1601-1609. PubMed ID: 28895191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial.
    Banke A; Fosbøl EL; Møller JE; Gislason GH; Andersen M; Bernsdorf M; Jensen MB; Schou M; Ejlertsen B
    Eur J Heart Fail; 2018 Oct; 20(10):1447-1453. PubMed ID: 29493047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
    Ventura GJ
    J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of epirubicin in advanced breast cancer.
    Conte PF; Gennari A; Landucci E; Orlandini C
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S46-51. PubMed ID: 11970749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of early epirubicin cardiotoxicity in women with breast cancer.
    Sobić-Saranović D; Pavlović S; Susnjar S; Neskovi c-Konstantinović Z; Jelić S
    Anticancer Res; 1997; 17(5B):3889-91. PubMed ID: 9427798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epirubicin: a new entry in the list of fetal cardiotoxic drugs? Intrauterine death of one fetus in a twin pregnancy. Case report and review of literature.
    Framarino-dei-Malatesta M; Perrone G; Giancotti A; Ventriglia F; Derme M; Iannini I; Tibaldi V; Galoppi P; Sammartino P; Cascialli G; Brunelli R
    BMC Cancer; 2015 Dec; 15():951. PubMed ID: 26673573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
    Ryberg M; Nielsen D; Skovsgaard T; Hansen J; Jensen BV; Dombernowsky P
    J Clin Oncol; 1998 Nov; 16(11):3502-8. PubMed ID: 9817267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques.
    Meinardi MT; Van Der Graaf WT; Gietema JA; Van Den Berg MP; Sleijfer DT; De Vries EG; Haaksma J; Boomsma F; Van Veldhuisen DJ
    Heart; 2002 Jul; 88(1):81-2. PubMed ID: 12067953
    [No Abstract]   [Full Text] [Related]  

  • 34. Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up.
    Ito Y; Mukaiyama T; Ogawa M; Mizunuma N; Takahashi S; Aiba K; Horikoshi N
    Cancer Chemother Pharmacol; 1999; 43(1):8-12. PubMed ID: 9923535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy.
    Li H; Hu B; Guo Z; Jiang X; Su X; Zhang X
    Yonsei Med J; 2019 Jan; 60(1):30-37. PubMed ID: 30554488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of epirubicin-based adjuvant therapy in breast cancer.
    Untch M; von Koch F; Kahlert S; Konecny G
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S41-5. PubMed ID: 15959941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.
    Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P
    Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective evaluation of anthracycline-related early cardiac damage: how do we monitor it?
    Ciotti R; Ucci G; Belotti G; Facchi E; Cremonesi M; Gatti C; Baccheta G
    J Clin Oncol; 2001 Nov; 19(22):4269-70. PubMed ID: 11709572
    [No Abstract]   [Full Text] [Related]  

  • 39. Tissue-Doppler assessment of cardiac left ventricular function during short-term adjuvant epirubicin therapy for breast cancer.
    Appel JM; Sogaard P; Mortensen CE; Skagen K; Nielsen DL
    J Am Soc Echocardiogr; 2011 Feb; 24(2):200-6. PubMed ID: 21227647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of high dose epirubicin in patients with advanced breast carcinoma.
    Miller DK; Munshi N; Loesch D; Einhorn LE; Sledge GW
    Cancer; 2000 Jan; 88(2):375-80. PubMed ID: 10640971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.